4.65 (-%)
As of Nov 21, 2024
Source:
We are a clinical stage biopharmaceutical company using our proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. We are initially focusing our efforts on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Our PTR platform incorporates a proprietary Erosion Barrier Layer (EBL) designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets.
Country | United States |
Headquarters | kansas city, kansas |
Phone Number | (913) 942-2300 |
Industry | |
CEO | Shane J. Schaffer |
Website |